All In Biotech

Drug Trial Radar · NCT03168841

Efficacy and Safety of Efinaconazole 10% Solution in the Treatment of Onychomycosis in Diabetic Patients

Last checked: Nov 20, 2026Latest source record: Oct 30, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

40

Actual

Start

Jun 6, 2017

Primary completion

Jan 9, 2019

Study completion Jan 9, 2019

Sponsor

Lead sponsor
Western University of Health SciencesAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
May 30, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Onychomycosis, a common pathology of the toenails, is even more prevalent among diabetic subjects. Nearly 26 million Americans suffer from diabetes, and approximately one-third of subjects with diabetes have toenail onychomycosis. Numerous studies have addressed the efficacy and safety of both topical and oral antifungal treatment options for onychomycosis in diabetic subjects. However, no study to date has specifically addressed the efficacy and safety of efinaconazole among diabetic subjects. The objective of this noncomparative, uncontrolled study is to determine the efficacy of topical efinaconazole 10% for toenail onychomycosis among subjects with diabetes mellitus. Specific indicators to measure efficacy of treatment will be the mycological cure rate, complete cure rate, and treatment success. Furthermore, an additional goal of the study is to gain knowledge of safety in the setting of a cohort of diabetic subjects

Conditions

  • Onychomycosis

Interventions

  • Efinaconazole TopicalDrug

    Enrolled subjects will be dispensed medical for topical application, and followed for a period of 50 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Primary Endpoint - EfficacyTime frame: 50 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Western University of Health Sciences

    Pomona, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.